Pre-Conference Tutorials, Monday, March 8, 2010, 09:00

Welcome from the EuroMeeting 2010 Co-Chairs
Bruno Flamion and Kerstin Franzén
Dear Colleague,
It is our pleasure to invite you to participate in the 22nd Annual
EuroMeeting in Monaco, 8-10 March 2010. Three days of discussion,
sharing of experience, debating and networking will show the vitality of
drug development in Europe and across the world. Whether you are a
session chair, speaker, tutorial instructor or attendee, and whether you
are from a regulatory agency, academia, industry or a patient group, or
a student or young professional, we believe you can play a key role in
building the success of the EuroMeeting and ensuring its place as one of
the most important European conferences for professionals involved in the
development of medicines.
When deciding on the themes, we have chosen the integrated, multi-disciplinary
approach. The aim is to generate interest from as many disciplines as possible and
to create a lively platform for a debate on development but also market access of
medicines in Europe. We are aware that many of you will be looking for your
specific area of interest in the programme such as non-clinical aspects,
statistics, IT, etc. The Session Finder on pages 8-9 will highlight which
sessions will discuss these aspects. We trust that you will build your own
theme. Why not take this opportunity to look across the board and find
exciting cross-disciplinary topics?
Monaco is an exciting location, well-known to most people. Despite
being a small country, it has a lot to offer and is very hospitable and
culturally interesting. No doubt there are numerous challenges around
but we strongly believe you should not miss this opportunity to bring
your contribution to the debate on drug development. Make your plans
to come to Monaco in March 2010!
Bruno Flamion and Kerstin Franzén
Programme Advisors
Melek Bostanci Onol, DRA Manager, Boehringer
Ingelheim Ilac Ticaret A.S., Turkey
Daniel Brasseur, Chair PDCO, Senior Member,
Federal Drug Agency, Belgium
Emmanuel Chantelot, Executive Director, European
Biopharmaceutical Enterprises (EBE), Belgium
Daan Crommelin, Scientific Director, Top Institute
Pharma, The Netherlands
Anne de Bock, Portfolio Leader Oncology & Antiinfectives,
AstraZeneca, Belgium
Hans-Georg Eichler, Senior Medical Officer,
European Medicines Agency, EU
Julianne Hull, Senior Director, Global Development
Data Operations, Wyeth Research, UK
Robert Hemmings, Statistics Unit Manager, MHRA,
UK
Sabina Hoekstra-van den Bosch, Senior Advisor,
Department of Pharmaceutical Affairs and Medical
Technology, Ministry of Health, Welfare and Sport,
The Netherlands
Tim Kievits, CEO, PamGene, Chair of EuropaBio
Personalised Medicines Working Group,
The Netherlands
Ingrid Klingmann, Managing
Director, Pharmaplex, Belgium
Jytte Lyngvig, Chief Executive Officer, Danish
Medicines Agency, Denmark
José Ramet, Professor, University of Antwerp,
Chairman, Paediatric Department, University
Hospital Antwerp and Queen Paola Children’s
Hospital, Belgium
Andrea Rappagliosi, Vice President European
Government Affairs & Head of Brussels Office,
GlaxoSmithKline, UK
Jean-Louis Robert, Head, Department of Medicines
Control Laboratory, National Health Laboratory,
Luxembourg
Malcolm Rowland, Emeritus Professor, School of
Pharmacy and Pharmaceutical Sciences University
of Manchester, England
Agnès Saint Raymond, Head of Human Medicines
Special Areas, European Medicines Agency, EU
Christian Schneider, Chair CAT, European Medicines
Agency, Acting Head, Division EU
Cooperation/Microbiology, Paul-Ehrlich-Institut,
Germany
Bruno Flamion
Professor, Clinical Pharmacology, University of Namur, Belgium
and Chair, CHMP, Scientific Advice Working Party, European
Medicines Agency
Bruno Flamion is an MD who practised internal medicine and nephrology in
Belgium. He was a Research Fellow at the NIH (1988-1992) and with the
Belgian National Fund for Scientific Research (1992-1996) and later got a PhD
in physiological sciences from the University of Brussels. He is now Full
Professor of Physiology and Pharmacology at the University of Namur,
Belgium, where he heads a molecular physiology lab. He has been involved as
a medical expert for the Belgian Federal Agency for Medicines and Health
Products (FAMHP) since 1999 and for the European Medicines Agency: CHMP,
PK group, Pharmacogenomics, and more recently CAT (Committee for
Advanced Therapies). His favourite activity is chairing the Scientific Advice
Working Party.
Kerstin Franzén
Senior Director, Regulatory Policy & Intelligence,
Pfizer, Sweden
Kerstin Franzén has a background in Regulatory Affairs covering 29 years.
After an academic degree at Uppsala University, M Pharm Sci, she joined the
pharmaceutical industry, first for a short period in the marketing area, and
then went into the regulatory arena. The first seven years were spent with the
Roche affiliate in Sweden, followed by a move to the Swiss headquarters
where she stayed for four years, still in Regulatory Affairs. In 1990 she decided
to join Kabi Pharmacia and go back to Sweden. This company went through
a number of mergers and acquisitions, which eventually led to her current
position with Pfizer in Regulatory Policy & Intelligence, an area she has been
involved in since 1998.
Beatriz Silva Lima, CHMP, European Medicines
Agency, Professor, Pharmacology, University of
Lisbon, INFARMED, Portugal
Susie Stephens, Director of Biomedical Informatics,
Johnson and Johnson Pharmaceutical R&D, UK
Wolfgang Summa, Executive Vice President,
Business Development, OmniComm Systems,
Germany
Erik Tambuyzer, Senior Vice President, Corporate
Affairs, Europe and International, Genzyme, Belgium
Catherine Tuleu, Senior Lecturer and Deputy
Director, The School of Pharmacy, University of
London, UK
Noël Wathion, Head of Patient Health Protection,
European Medicines Agency, EU
Paul Woods, Global Compliance Policy Director,
AstraZeneca, UK
3